Recent Updates
Recently added Catalysts

Pre-radiation temozolomide.

Phase 2

High Grade Gliomas | Small molecule | Oncology |The Cooper Companies, Inc.|Last Updated: Feb 26, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment70
FDA Designations
No designations recorded
Clinical trial landscape

Pre-radiation temozolomide. · 1 trial · 4 indications

Phase 2 1
NCT07439172Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.High Grade Gliomas
NOT YET_RECRUITING70 Analytics
PHASE2NOT YET_RECRUITING
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
High Grade Gliomas
NCT0743917270
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
Pre-radiation temozolomide.DRUGPatients will receive 2 cycles of pre-radiation temozolomide (200mg/m\^2). Cycles are 28-days in length. Participants will take temozolomide on days 1-5 of the 28-day cycle.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07439172studyFirstPostDate: changed